Cellectis (CLLS) Current Deferred Revenue (2016 - 2026)

Cellectis' Current Deferred Revenue history runs 13 years deep, the most recent figure standing at $93.1 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 17.87% year-over-year to $93.1 million; the TTM figure through Mar 2026 stood at $93.1 million (down 17.87% YoY), while the FY2025 annual figure was $96.8 million, down 13.69% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $93.1 million, down from $96.8 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $122.0 million in Q3 2024, with the low at $59000.0 in Q4 2022.
• The 5-year median for Current Deferred Revenue is $94.0 million (2025), against an average of $64.4 million.
• The sharpest annual moves came in 2022 and 2023: Current Deferred Revenue sank 80.4% in 2022, then jumped 186891.53% in 2023.
• Cellectis' Current Deferred Revenue stood at $59000.0 in 2022, then surged by 186891.53% to $110.3 million in 2023, then grew by 1.66% to $112.2 million in 2024, then decreased by 13.69% to $96.8 million in 2025, then declined by 3.86% to $93.1 million in 2026.
• Business Quant data shows CLLS's Current Deferred Revenue at $93.1 million in Q1 2026, $96.8 million in Q4 2025, and $94.0 million in Q3 2025.